- Home
- SMXT vs CUE Comparison
SMXT vs CUE Comparison
Compare SMXT & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMXT
- CUE
- Stock Information
- Founded
- SMXT 2008
- CUE 2014
- Country
- SMXT United States
- CUE United States
- Employees
- SMXT N/A
- CUE N/A
- Industry
- SMXT
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- SMXT
- CUE Health Care
- Exchange
- SMXT NYSE
- CUE Nasdaq
- Market Cap
- SMXT 53.6M
- CUE 57.7M
- IPO Year
- SMXT 2024
- CUE 2018
- Fundamental
- Price
- SMXT $1.05
- CUE $0.88
- Analyst Decision
- SMXT
- CUE Strong Buy
- Analyst Count
- SMXT 0
- CUE 3
- Target Price
- SMXT N/A
- CUE $3.00
- AVG Volume (30 Days)
- SMXT 232.5K
- CUE 554.5K
- Earning Date
- SMXT 08-13-2025
- CUE 08-13-2025
- Dividend Yield
- SMXT N/A
- CUE N/A
- EPS Growth
- SMXT N/A
- CUE N/A
- EPS
- SMXT N/A
- CUE N/A
- Revenue
- SMXT $24,150,276.00
- CUE $7,991,000.00
- Revenue This Year
- SMXT N/A
- CUE N/A
- Revenue Next Year
- SMXT N/A
- CUE $23.84
- P/E Ratio
- SMXT N/A
- CUE N/A
- Revenue Growth
- SMXT N/A
- CUE 13.83
- 52 Week Low
- SMXT $0.60
- CUE $0.45
- 52 Week High
- SMXT $4.45
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- SMXT N/A
- CUE 61.23
- Support Level
- SMXT N/A
- CUE $0.84
- Resistance Level
- SMXT N/A
- CUE $0.98
- Average True Range (ATR)
- SMXT 0.00
- CUE 0.10
- MACD
- SMXT 0.00
- CUE 0.01
- Stochastic Oscillator
- SMXT 0.00
- CUE 57.97
About SMXT SOLARMAX TECHNOLOGY INC
SolarMax Technology Inc is an integrated solar and renewable energy company. It operates in two segments namely the United States and China. The United States business includes the sale and installation of photovoltaic and battery backup systems. China operations consist of operating and maintaining solar farm projects and identifying and procuring solar farm projects for resale to third parties. Some of its products are LG Solar Panels, QCELL Solar Panels, Panasonic Solar Panels, and others. The company generates a majority of its revenue from the Solar energy systems.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.